nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—SBK3—adipose tissue—Graves' disease	0.00963	0.0184	CbGeAlD
Crizotinib—SBK3—thyroid gland—Graves' disease	0.00833	0.016	CbGeAlD
Crizotinib—Interstitial lung disease—Propylthiouracil—Graves' disease	0.0082	0.15	CcSEcCtD
Crizotinib—NEK9—connective tissue—Graves' disease	0.00555	0.0106	CbGeAlD
Crizotinib—IKBKE—thyroid gland—Graves' disease	0.00515	0.00986	CbGeAlD
Crizotinib—SIK2—connective tissue—Graves' disease	0.00499	0.00957	CbGeAlD
Crizotinib—Hepatic failure—Propylthiouracil—Graves' disease	0.00469	0.0859	CcSEcCtD
Crizotinib—EPHA8—eye—Graves' disease	0.00462	0.00885	CbGeAlD
Crizotinib—MAPK7—connective tissue—Graves' disease	0.0045	0.00862	CbGeAlD
Crizotinib—MET—eye—Graves' disease	0.00437	0.00837	CbGeAlD
Crizotinib—MET—connective tissue—Graves' disease	0.00421	0.00807	CbGeAlD
Crizotinib—CDK7—connective tissue—Graves' disease	0.00407	0.0078	CbGeAlD
Crizotinib—ACVR1B—eye—Graves' disease	0.00404	0.00774	CbGeAlD
Crizotinib—EPHA3—eye—Graves' disease	0.00404	0.00774	CbGeAlD
Crizotinib—PRKD1—adipose tissue—Graves' disease	0.00388	0.00744	CbGeAlD
Crizotinib—LIMK1—adipose tissue—Graves' disease	0.00383	0.00734	CbGeAlD
Crizotinib—SIK2—adipose tissue—Graves' disease	0.00383	0.00734	CbGeAlD
Crizotinib—PRKD3—pituitary gland—Graves' disease	0.00375	0.00719	CbGeAlD
Crizotinib—Neuropathy peripheral—Methimazole—Graves' disease	0.00374	0.0686	CcSEcCtD
Crizotinib—PRKD3—adipose tissue—Graves' disease	0.00373	0.00716	CbGeAlD
Crizotinib—JAK3—connective tissue—Graves' disease	0.00371	0.00711	CbGeAlD
Crizotinib—DSTYK—pituitary gland—Graves' disease	0.00366	0.00701	CbGeAlD
Crizotinib—DSTYK—adipose tissue—Graves' disease	0.00364	0.00698	CbGeAlD
Crizotinib—STK4—connective tissue—Graves' disease	0.00364	0.00698	CbGeAlD
Crizotinib—EPHA5—eye—Graves' disease	0.00357	0.00685	CbGeAlD
Crizotinib—CASK—adipose tissue—Graves' disease	0.00356	0.00683	CbGeAlD
Crizotinib—MAPK7—pituitary gland—Graves' disease	0.00346	0.00664	CbGeAlD
Crizotinib—MAPK7—adipose tissue—Graves' disease	0.00345	0.00661	CbGeAlD
Crizotinib—ALK—connective tissue—Graves' disease	0.00344	0.0066	CbGeAlD
Crizotinib—TYRO3—connective tissue—Graves' disease	0.00344	0.0066	CbGeAlD
Crizotinib—IGF1R—eye—Graves' disease	0.00343	0.00658	CbGeAlD
Crizotinib—LYN—connective tissue—Graves' disease	0.00343	0.00656	CbGeAlD
Crizotinib—FES—adipose tissue—Graves' disease	0.00342	0.00654	CbGeAlD
Crizotinib—PRKD1—thyroid gland—Graves' disease	0.00336	0.00644	CbGeAlD
Crizotinib—STK3—eye—Graves' disease	0.00334	0.0064	CbGeAlD
Crizotinib—LIMK1—thyroid gland—Graves' disease	0.00332	0.00636	CbGeAlD
Crizotinib—IGF1R—connective tissue—Graves' disease	0.00331	0.00634	CbGeAlD
Crizotinib—MET—pituitary gland—Graves' disease	0.00324	0.00621	CbGeAlD
Crizotinib—PRKD3—thyroid gland—Graves' disease	0.00323	0.00619	CbGeAlD
Crizotinib—MET—adipose tissue—Graves' disease	0.00323	0.00619	CbGeAlD
Crizotinib—TESK1—eye—Graves' disease	0.00323	0.00619	CbGeAlD
Crizotinib—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00318	0.0583	CcSEcCtD
Crizotinib—DSTYK—thyroid gland—Graves' disease	0.00315	0.00605	CbGeAlD
Crizotinib—MERTK—eye—Graves' disease	0.00314	0.00602	CbGeAlD
Crizotinib—CDK7—adipose tissue—Graves' disease	0.00312	0.00599	CbGeAlD
Crizotinib—TAOK2—pituitary gland—Graves' disease	0.00311	0.00596	CbGeAlD
Crizotinib—TESK1—connective tissue—Graves' disease	0.00311	0.00596	CbGeAlD
Crizotinib—TAOK2—adipose tissue—Graves' disease	0.0031	0.00594	CbGeAlD
Crizotinib—CASK—thyroid gland—Graves' disease	0.00308	0.00591	CbGeAlD
Crizotinib—ACVR1—eye—Graves' disease	0.00304	0.00582	CbGeAlD
Crizotinib—MAP3K12—eye—Graves' disease	0.00304	0.00582	CbGeAlD
Crizotinib—MAPK7—thyroid gland—Graves' disease	0.00299	0.00572	CbGeAlD
Crizotinib—ACVR1B—adipose tissue—Graves' disease	0.00299	0.00572	CbGeAlD
Crizotinib—EPHA3—adipose tissue—Graves' disease	0.00299	0.00572	CbGeAlD
Crizotinib—FES—thyroid gland—Graves' disease	0.00296	0.00567	CbGeAlD
Crizotinib—ACVR1—connective tissue—Graves' disease	0.00293	0.00561	CbGeAlD
Crizotinib—FLT3—connective tissue—Graves' disease	0.00293	0.00561	CbGeAlD
Crizotinib—JAK3—adipose tissue—Graves' disease	0.00285	0.00546	CbGeAlD
Crizotinib—DCLK1—pituitary gland—Graves' disease	0.00284	0.00545	CbGeAlD
Crizotinib—DCLK1—adipose tissue—Graves' disease	0.00283	0.00542	CbGeAlD
Crizotinib—MET—thyroid gland—Graves' disease	0.0028	0.00536	CbGeAlD
Crizotinib—STK4—adipose tissue—Graves' disease	0.0028	0.00536	CbGeAlD
Crizotinib—BMP2K—connective tissue—Graves' disease	0.00276	0.00529	CbGeAlD
Crizotinib—RIPK2—eye—Graves' disease	0.00275	0.00526	CbGeAlD
Crizotinib—CDK7—thyroid gland—Graves' disease	0.0027	0.00518	CbGeAlD
Crizotinib—TAOK2—thyroid gland—Graves' disease	0.00268	0.00514	CbGeAlD
Crizotinib—Leukopenia—Methimazole—Graves' disease	0.00267	0.049	CcSEcCtD
Crizotinib—PTK2B—connective tissue—Graves' disease	0.00267	0.00511	CbGeAlD
Crizotinib—ALK—pituitary gland—Graves' disease	0.00265	0.00508	CbGeAlD
Crizotinib—FER—pituitary gland—Graves' disease	0.00265	0.00508	CbGeAlD
Crizotinib—EPHA5—pituitary gland—Graves' disease	0.00265	0.00508	CbGeAlD
Crizotinib—RIPK2—connective tissue—Graves' disease	0.00264	0.00507	CbGeAlD
Crizotinib—FER—adipose tissue—Graves' disease	0.00264	0.00506	CbGeAlD
Crizotinib—TNK1—pituitary gland—Graves' disease	0.00263	0.00503	CbGeAlD
Crizotinib—MAP4K1—adipose tissue—Graves' disease	0.00259	0.00496	CbGeAlD
Crizotinib—BMPR1B—adipose tissue—Graves' disease	0.00259	0.00496	CbGeAlD
Crizotinib—ACVR1B—thyroid gland—Graves' disease	0.00258	0.00495	CbGeAlD
Crizotinib—EPHA3—thyroid gland—Graves' disease	0.00258	0.00495	CbGeAlD
Crizotinib—TBK1—eye—Graves' disease	0.00255	0.00488	CbGeAlD
Crizotinib—TNK2—adipose tissue—Graves' disease	0.00254	0.00486	CbGeAlD
Crizotinib—IGF1R—adipose tissue—Graves' disease	0.00254	0.00486	CbGeAlD
Crizotinib—TYK2—eye—Graves' disease	0.00253	0.00485	CbGeAlD
Crizotinib—MAP4K2—pituitary gland—Graves' disease	0.00251	0.00482	CbGeAlD
Crizotinib—MAP3K2—connective tissue—Graves' disease	0.00251	0.0048	CbGeAlD
Crizotinib—MAP4K2—adipose tissue—Graves' disease	0.0025	0.0048	CbGeAlD
Crizotinib—Dysgeusia—Propylthiouracil—Graves' disease	0.00248	0.0455	CcSEcCtD
Crizotinib—STK3—pituitary gland—Graves' disease	0.00248	0.00475	CbGeAlD
Crizotinib—TIE1—adipose tissue—Graves' disease	0.00247	0.00473	CbGeAlD
Crizotinib—STK3—adipose tissue—Graves' disease	0.00247	0.00473	CbGeAlD
Crizotinib—JAK3—thyroid gland—Graves' disease	0.00247	0.00472	CbGeAlD
Crizotinib—PTK2—connective tissue—Graves' disease	0.00246	0.00471	CbGeAlD
Crizotinib—RPS6KB1—eye—Graves' disease	0.00245	0.0047	CbGeAlD
Crizotinib—DCLK1—thyroid gland—Graves' disease	0.00245	0.00469	CbGeAlD
Crizotinib—TYK2—connective tissue—Graves' disease	0.00244	0.00467	CbGeAlD
Crizotinib—Oedema—Methimazole—Graves' disease	0.00243	0.0446	CcSEcCtD
Crizotinib—AXL—eye—Graves' disease	0.00243	0.00465	CbGeAlD
Crizotinib—STK4—thyroid gland—Graves' disease	0.00242	0.00464	CbGeAlD
Crizotinib—AURKA—pituitary gland—Graves' disease	0.00242	0.00463	CbGeAlD
Crizotinib—TESK1—pituitary gland—Graves' disease	0.0024	0.00459	CbGeAlD
Crizotinib—TESK1—adipose tissue—Graves' disease	0.00239	0.00457	CbGeAlD
Crizotinib—RPS6KB1—connective tissue—Graves' disease	0.00236	0.00453	CbGeAlD
Crizotinib—AXL—connective tissue—Graves' disease	0.00234	0.00448	CbGeAlD
Crizotinib—MERTK—pituitary gland—Graves' disease	0.00233	0.00447	CbGeAlD
Crizotinib—MERTK—adipose tissue—Graves' disease	0.00232	0.00445	CbGeAlD
Crizotinib—FER—thyroid gland—Graves' disease	0.00229	0.00438	CbGeAlD
Crizotinib—LIMK2—pituitary gland—Graves' disease	0.00228	0.00437	CbGeAlD
Crizotinib—NUAK2—pituitary gland—Graves' disease	0.00227	0.00435	CbGeAlD
Crizotinib—LIMK2—adipose tissue—Graves' disease	0.00227	0.00435	CbGeAlD
Crizotinib—Leukopenia—Propylthiouracil—Graves' disease	0.00227	0.0416	CcSEcCtD
Crizotinib—TNK1—thyroid gland—Graves' disease	0.00226	0.00434	CbGeAlD
Crizotinib—NUAK2—adipose tissue—Graves' disease	0.00226	0.00434	CbGeAlD
Crizotinib—ACVR1—pituitary gland—Graves' disease	0.00226	0.00432	CbGeAlD
Crizotinib—MAP3K12—pituitary gland—Graves' disease	0.00226	0.00432	CbGeAlD
Crizotinib—MAP3K12—adipose tissue—Graves' disease	0.00225	0.0043	CbGeAlD
Crizotinib—ACVR1—adipose tissue—Graves' disease	0.00225	0.0043	CbGeAlD
Crizotinib—MAP4K1—thyroid gland—Graves' disease	0.00224	0.00429	CbGeAlD
Crizotinib—BMPR1B—thyroid gland—Graves' disease	0.00224	0.00429	CbGeAlD
Crizotinib—EPHB4—connective tissue—Graves' disease	0.00223	0.00428	CbGeAlD
Crizotinib—JAK2—connective tissue—Graves' disease	0.00222	0.00425	CbGeAlD
Crizotinib—STK35—adipose tissue—Graves' disease	0.0022	0.00422	CbGeAlD
Crizotinib—IGF1R—thyroid gland—Graves' disease	0.0022	0.00421	CbGeAlD
Crizotinib—TNK2—thyroid gland—Graves' disease	0.0022	0.00421	CbGeAlD
Crizotinib—Paraesthesia—Methimazole—Graves' disease	0.00219	0.0401	CcSEcCtD
Crizotinib—MAP4K2—thyroid gland—Graves' disease	0.00217	0.00415	CbGeAlD
Crizotinib—ABL2—pituitary gland—Graves' disease	0.00215	0.00413	CbGeAlD
Crizotinib—ABL2—adipose tissue—Graves' disease	0.00214	0.00411	CbGeAlD
Crizotinib—Dyspepsia—Methimazole—Graves' disease	0.00214	0.0393	CcSEcCtD
Crizotinib—TEK—connective tissue—Graves' disease	0.00214	0.0041	CbGeAlD
Crizotinib—STK3—thyroid gland—Graves' disease	0.00214	0.0041	CbGeAlD
Crizotinib—TIE1—thyroid gland—Graves' disease	0.00214	0.0041	CbGeAlD
Crizotinib—BMP2K—adipose tissue—Graves' disease	0.00212	0.00406	CbGeAlD
Crizotinib—AURKA—thyroid gland—Graves' disease	0.00208	0.00399	CbGeAlD
Crizotinib—Oedema—Propylthiouracil—Graves' disease	0.00207	0.038	CcSEcCtD
Crizotinib—TESK1—thyroid gland—Graves' disease	0.00207	0.00396	CbGeAlD
Crizotinib—YES1—eye—Graves' disease	0.00205	0.00393	CbGeAlD
Crizotinib—PTK2B—adipose tissue—Graves' disease	0.00205	0.00392	CbGeAlD
Crizotinib—RIPK2—pituitary gland—Graves' disease	0.00204	0.0039	CbGeAlD
Crizotinib—RIPK2—adipose tissue—Graves' disease	0.00203	0.00389	CbGeAlD
Crizotinib—TAOK3—eye—Graves' disease	0.00202	0.00388	CbGeAlD
Crizotinib—MERTK—thyroid gland—Graves' disease	0.00201	0.00385	CbGeAlD
Crizotinib—YES1—connective tissue—Graves' disease	0.00198	0.00378	CbGeAlD
Crizotinib—SRC—eye—Graves' disease	0.00197	0.00378	CbGeAlD
Crizotinib—EPHA4—pituitary gland—Graves' disease	0.00197	0.00377	CbGeAlD
Crizotinib—LIMK2—thyroid gland—Graves' disease	0.00197	0.00377	CbGeAlD
Crizotinib—EPHA4—adipose tissue—Graves' disease	0.00196	0.00376	CbGeAlD
Crizotinib—NUAK2—thyroid gland—Graves' disease	0.00196	0.00375	CbGeAlD
Crizotinib—TAOK3—connective tissue—Graves' disease	0.00195	0.00374	CbGeAlD
Crizotinib—ACVR1—thyroid gland—Graves' disease	0.00194	0.00373	CbGeAlD
Crizotinib—MAP3K12—thyroid gland—Graves' disease	0.00194	0.00373	CbGeAlD
Crizotinib—Body temperature increased—Methimazole—Graves' disease	0.00192	0.0353	CcSEcCtD
Crizotinib—MAP3K2—adipose tissue—Graves' disease	0.00192	0.00369	CbGeAlD
Crizotinib—STK35—thyroid gland—Graves' disease	0.00191	0.00365	CbGeAlD
Crizotinib—SRC—connective tissue—Graves' disease	0.0019	0.00364	CbGeAlD
Crizotinib—TBK1—pituitary gland—Graves' disease	0.00189	0.00363	CbGeAlD
Crizotinib—PTK2—pituitary gland—Graves' disease	0.00189	0.00363	CbGeAlD
Crizotinib—PTK2—adipose tissue—Graves' disease	0.00188	0.00361	CbGeAlD
Crizotinib—TBK1—adipose tissue—Graves' disease	0.00188	0.00361	CbGeAlD
Crizotinib—TYK2—pituitary gland—Graves' disease	0.00188	0.0036	CbGeAlD
Crizotinib—TYK2—adipose tissue—Graves' disease	0.00187	0.00359	CbGeAlD
Crizotinib—Paraesthesia—Propylthiouracil—Graves' disease	0.00186	0.0341	CcSEcCtD
Crizotinib—ABL2—thyroid gland—Graves' disease	0.00186	0.00356	CbGeAlD
Crizotinib—IRAK1—adipose tissue—Graves' disease	0.00185	0.00354	CbGeAlD
Crizotinib—BMP2K—thyroid gland—Graves' disease	0.00183	0.00351	CbGeAlD
Crizotinib—Dyspepsia—Propylthiouracil—Graves' disease	0.00182	0.0334	CcSEcCtD
Crizotinib—RPS6KB1—pituitary gland—Graves' disease	0.00182	0.00349	CbGeAlD
Crizotinib—RPS6KB1—adipose tissue—Graves' disease	0.00181	0.00347	CbGeAlD
Crizotinib—FGR—pituitary gland—Graves' disease	0.00181	0.00347	CbGeAlD
Crizotinib—AXL—pituitary gland—Graves' disease	0.0018	0.00345	CbGeAlD
Crizotinib—LCK—adipose tissue—Graves' disease	0.0018	0.00345	CbGeAlD
Crizotinib—FGR—adipose tissue—Graves' disease	0.0018	0.00345	CbGeAlD
Crizotinib—AXL—adipose tissue—Graves' disease	0.00179	0.00344	CbGeAlD
Crizotinib—PTK2B—thyroid gland—Graves' disease	0.00177	0.00339	CbGeAlD
Crizotinib—CSF1R—eye—Graves' disease	0.00177	0.00339	CbGeAlD
Crizotinib—RIPK2—thyroid gland—Graves' disease	0.00176	0.00337	CbGeAlD
Crizotinib—SLK—pituitary gland—Graves' disease	0.00173	0.00332	CbGeAlD
Crizotinib—SLK—adipose tissue—Graves' disease	0.00173	0.00331	CbGeAlD
Crizotinib—EPHB4—pituitary gland—Graves' disease	0.00172	0.0033	CbGeAlD
Crizotinib—EPHB4—adipose tissue—Graves' disease	0.00171	0.00329	CbGeAlD
Crizotinib—JAK2—pituitary gland—Graves' disease	0.00171	0.00328	CbGeAlD
Crizotinib—CSF1R—connective tissue—Graves' disease	0.00171	0.00327	CbGeAlD
Crizotinib—JAK2—adipose tissue—Graves' disease	0.0017	0.00326	CbGeAlD
Crizotinib—EPHA4—thyroid gland—Graves' disease	0.0017	0.00325	CbGeAlD
Crizotinib—EPHA2—pituitary gland—Graves' disease	0.00169	0.00324	CbGeAlD
Crizotinib—EPHA2—adipose tissue—Graves' disease	0.00168	0.00322	CbGeAlD
Crizotinib—MAP3K2—thyroid gland—Graves' disease	0.00167	0.00319	CbGeAlD
Crizotinib—MAP3K3—pituitary gland—Graves' disease	0.00165	0.00316	CbGeAlD
Crizotinib—MAP4K5—pituitary gland—Graves' disease	0.00165	0.00316	CbGeAlD
Crizotinib—TEK—pituitary gland—Graves' disease	0.00165	0.00316	CbGeAlD
Crizotinib—MAP3K3—adipose tissue—Graves' disease	0.00164	0.00314	CbGeAlD
Crizotinib—MAP4K5—adipose tissue—Graves' disease	0.00164	0.00314	CbGeAlD
Crizotinib—TEK—adipose tissue—Graves' disease	0.00164	0.00314	CbGeAlD
Crizotinib—Body temperature increased—Propylthiouracil—Graves' disease	0.00164	0.03	CcSEcCtD
Crizotinib—PTK2—thyroid gland—Graves' disease	0.00163	0.00312	CbGeAlD
Crizotinib—TBK1—thyroid gland—Graves' disease	0.00163	0.00312	CbGeAlD
Crizotinib—TYK2—thyroid gland—Graves' disease	0.00162	0.0031	CbGeAlD
Crizotinib—IRAK1—thyroid gland—Graves' disease	0.0016	0.00306	CbGeAlD
Crizotinib—EPHB6—pituitary gland—Graves' disease	0.00157	0.00302	CbGeAlD
Crizotinib—RPS6KB1—thyroid gland—Graves' disease	0.00157	0.00301	CbGeAlD
Crizotinib—EPHB6—adipose tissue—Graves' disease	0.00157	0.00301	CbGeAlD
Crizotinib—FGR—thyroid gland—Graves' disease	0.00156	0.00299	CbGeAlD
Crizotinib—LCK—thyroid gland—Graves' disease	0.00156	0.00299	CbGeAlD
Crizotinib—AXL—thyroid gland—Graves' disease	0.00155	0.00298	CbGeAlD
Crizotinib—Vomiting—Methimazole—Graves' disease	0.00155	0.0284	CcSEcCtD
Crizotinib—Rash—Methimazole—Graves' disease	0.00153	0.0281	CcSEcCtD
Crizotinib—Dermatitis—Methimazole—Graves' disease	0.00153	0.0281	CcSEcCtD
Crizotinib—YES1—pituitary gland—Graves' disease	0.00152	0.00292	CbGeAlD
Crizotinib—YES1—adipose tissue—Graves' disease	0.00152	0.0029	CbGeAlD
Crizotinib—TAOK3—pituitary gland—Graves' disease	0.0015	0.00288	CbGeAlD
Crizotinib—STK10—adipose tissue—Graves' disease	0.0015	0.00288	CbGeAlD
Crizotinib—TAOK3—adipose tissue—Graves' disease	0.0015	0.00287	CbGeAlD
Crizotinib—SLK—thyroid gland—Graves' disease	0.00149	0.00286	CbGeAlD
Crizotinib—EPHB4—thyroid gland—Graves' disease	0.00148	0.00284	CbGeAlD
Crizotinib—JAK2—thyroid gland—Graves' disease	0.00147	0.00282	CbGeAlD
Crizotinib—SRC—adipose tissue—Graves' disease	0.00146	0.00279	CbGeAlD
Crizotinib—EPHA2—thyroid gland—Graves' disease	0.00146	0.00279	CbGeAlD
Crizotinib—Nausea—Methimazole—Graves' disease	0.00145	0.0265	CcSEcCtD
Crizotinib—TEK—thyroid gland—Graves' disease	0.00142	0.00272	CbGeAlD
Crizotinib—MAP3K3—thyroid gland—Graves' disease	0.00142	0.00272	CbGeAlD
Crizotinib—MAP4K5—thyroid gland—Graves' disease	0.00142	0.00272	CbGeAlD
Crizotinib—ABL1—eye—Graves' disease	0.0014	0.00268	CbGeAlD
Crizotinib—EPHB6—thyroid gland—Graves' disease	0.00136	0.0026	CbGeAlD
Crizotinib—ABL1—connective tissue—Graves' disease	0.00135	0.00258	CbGeAlD
Crizotinib—Vomiting—Propylthiouracil—Graves' disease	0.00132	0.0241	CcSEcCtD
Crizotinib—CSF1R—pituitary gland—Graves' disease	0.00131	0.00252	CbGeAlD
Crizotinib—YES1—thyroid gland—Graves' disease	0.00131	0.00251	CbGeAlD
Crizotinib—CSF1R—adipose tissue—Graves' disease	0.00131	0.00251	CbGeAlD
Crizotinib—Rash—Propylthiouracil—Graves' disease	0.00131	0.0239	CcSEcCtD
Crizotinib—Dermatitis—Propylthiouracil—Graves' disease	0.0013	0.0239	CcSEcCtD
Crizotinib—STK10—thyroid gland—Graves' disease	0.0013	0.00249	CbGeAlD
Crizotinib—TAOK3—thyroid gland—Graves' disease	0.00129	0.00248	CbGeAlD
Crizotinib—SRC—thyroid gland—Graves' disease	0.00126	0.00242	CbGeAlD
Crizotinib—Nausea—Propylthiouracil—Graves' disease	0.00123	0.0225	CcSEcCtD
Crizotinib—CSF1R—thyroid gland—Graves' disease	0.00113	0.00217	CbGeAlD
Crizotinib—ABL1—pituitary gland—Graves' disease	0.00104	0.00199	CbGeAlD
Crizotinib—ABL1—adipose tissue—Graves' disease	0.00103	0.00198	CbGeAlD
Crizotinib—ABL1—thyroid gland—Graves' disease	0.000896	0.00172	CbGeAlD
Crizotinib—CYP3A5—adipose tissue—Graves' disease	0.000606	0.00116	CbGeAlD
Crizotinib—ABCB1—pituitary gland—Graves' disease	0.000323	0.000619	CbGeAlD
Crizotinib—ABCB1—adipose tissue—Graves' disease	0.000322	0.000617	CbGeAlD
Crizotinib—ABCB1—thyroid gland—Graves' disease	0.000278	0.000534	CbGeAlD
Crizotinib—JAK2—Innate Immune System—HLA-B—Graves' disease	7.92e-05	0.000187	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HLA-A—Graves' disease	7.91e-05	0.000187	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL2RA—Graves' disease	7.89e-05	0.000186	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—IL1B—Graves' disease	7.86e-05	0.000186	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL2RA—Graves' disease	7.86e-05	0.000185	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HLA-A—Graves' disease	7.8e-05	0.000184	CbGpPWpGaD
Crizotinib—JAK2—Cytokine Signaling in Immune system—IL1B—Graves' disease	7.79e-05	0.000184	CbGpPWpGaD
Crizotinib—JAK3—Immune System—ICAM1—Graves' disease	7.78e-05	0.000184	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—CD4—Graves' disease	7.74e-05	0.000183	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—CD4—Graves' disease	7.74e-05	0.000183	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL2RA—Graves' disease	7.7e-05	0.000182	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TSHR—Graves' disease	7.69e-05	0.000182	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL2RA—Graves' disease	7.67e-05	0.000181	CbGpPWpGaD
Crizotinib—CDK7—Disease—HLA-A—Graves' disease	7.66e-05	0.000181	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—IFNG—Graves' disease	7.65e-05	0.00018	CbGpPWpGaD
Crizotinib—BLK—Immune System—HLA-A—Graves' disease	7.61e-05	0.00018	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CXCL10—Graves' disease	7.6e-05	0.000179	CbGpPWpGaD
Crizotinib—FGR—Immune System—HLA-A—Graves' disease	7.59e-05	0.000179	CbGpPWpGaD
Crizotinib—SRC—Disease—B3GNT2—Graves' disease	7.56e-05	0.000178	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HLA-A—Graves' disease	7.53e-05	0.000178	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TSHR—Graves' disease	7.46e-05	0.000176	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-DQB1—Graves' disease	7.46e-05	0.000176	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-DQB1—Graves' disease	7.41e-05	0.000175	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-DQB1—Graves' disease	7.36e-05	0.000174	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HLA-DRB1—Graves' disease	7.23e-05	0.000171	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—IL2RA—Graves' disease	7.22e-05	0.00017	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFIH1—Graves' disease	7.21e-05	0.00017	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—IL1B—Graves' disease	7.15e-05	0.000169	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—IL1B—Graves' disease	7.15e-05	0.000169	CbGpPWpGaD
Crizotinib—ABCB1—Allograft Rejection—TNF—Graves' disease	7.13e-05	0.000168	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HLA-DRB1—Graves' disease	7.13e-05	0.000168	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-DQB1—Graves' disease	6.98e-05	0.000165	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD8A—Graves' disease	6.97e-05	0.000164	CbGpPWpGaD
Crizotinib—BLK—Immune System—HLA-DRB1—Graves' disease	6.95e-05	0.000164	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—ICAM1—Graves' disease	6.94e-05	0.000164	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HLA-B—Graves' disease	6.94e-05	0.000164	CbGpPWpGaD
Crizotinib—FGR—Immune System—HLA-DRB1—Graves' disease	6.93e-05	0.000164	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD8A—Graves' disease	6.92e-05	0.000163	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-E—Graves' disease	6.92e-05	0.000163	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-E—Graves' disease	6.88e-05	0.000163	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HLA-DRB1—Graves' disease	6.88e-05	0.000162	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD8A—Graves' disease	6.87e-05	0.000162	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—CD4—Graves' disease	6.87e-05	0.000162	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—ICAM1—Graves' disease	6.84e-05	0.000161	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—IL1B—Graves' disease	6.82e-05	0.000161	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—CXCL10—Graves' disease	6.81e-05	0.000161	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—CD4—Graves' disease	6.78e-05	0.00016	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-DQB1—Graves' disease	6.77e-05	0.00016	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CXCL10—Graves' disease	6.77e-05	0.00016	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD40—Graves' disease	6.76e-05	0.00016	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD40—Graves' disease	6.73e-05	0.000159	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-B—Graves' disease	6.7e-05	0.000158	CbGpPWpGaD
Crizotinib—BLK—Immune System—ICAM1—Graves' disease	6.67e-05	0.000158	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CXCL10—Graves' disease	6.67e-05	0.000157	CbGpPWpGaD
Crizotinib—LYN—Immune System—CTLA4—Graves' disease	6.66e-05	0.000157	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-B—Graves' disease	6.66e-05	0.000157	CbGpPWpGaD
Crizotinib—FGR—Immune System—ICAM1—Graves' disease	6.65e-05	0.000157	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CTLA4—Graves' disease	6.63e-05	0.000157	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-B—Graves' disease	6.61e-05	0.000156	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—ICAM1—Graves' disease	6.6e-05	0.000156	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-DQB1—Graves' disease	6.56e-05	0.000155	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IFNG—Graves' disease	6.55e-05	0.000155	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GC—Graves' disease	6.55e-05	0.000155	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD8A—Graves' disease	6.52e-05	0.000154	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—CD4—Graves' disease	6.51e-05	0.000154	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-E—Graves' disease	6.47e-05	0.000153	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—CD4—Graves' disease	6.43e-05	0.000152	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—IL2RA—Graves' disease	6.39e-05	0.000151	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CXCL10—Graves' disease	6.39e-05	0.000151	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFIH1—Graves' disease	6.38e-05	0.000151	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD8A—Graves' disease	6.33e-05	0.000149	CbGpPWpGaD
Crizotinib—TBK1—Immune System—CD4—Graves' disease	6.33e-05	0.000149	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD40—Graves' disease	6.33e-05	0.000149	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IFNG—Graves' disease	6.28e-05	0.000148	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL2RA—Graves' disease	6.28e-05	0.000148	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-B—Graves' disease	6.27e-05	0.000148	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL2RA—Graves' disease	6.24e-05	0.000147	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—CD4—Graves' disease	6.24e-05	0.000147	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CTLA4—Graves' disease	6.23e-05	0.000147	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-A—Graves' disease	6.21e-05	0.000147	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL2RA—Graves' disease	6.19e-05	0.000146	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CXCL10—Graves' disease	6.19e-05	0.000146	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CXCL10—Graves' disease	6.19e-05	0.000146	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-A—Graves' disease	6.17e-05	0.000146	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HLA-B—Graves' disease	6.14e-05	0.000145	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD8A—Graves' disease	6.13e-05	0.000145	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-A—Graves' disease	6.12e-05	0.000145	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-B—Graves' disease	6.09e-05	0.000144	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—CD4—Graves' disease	6.06e-05	0.000143	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TSHR—Graves' disease	6.05e-05	0.000143	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	5.95e-05	0.00014	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IFNG—Graves' disease	5.92e-05	0.00014	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-B—Graves' disease	5.9e-05	0.000139	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL2RA—Graves' disease	5.87e-05	0.000139	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL1B—Graves' disease	5.84e-05	0.000138	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-A—Graves' disease	5.81e-05	0.000137	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL2RA—Graves' disease	5.81e-05	0.000137	CbGpPWpGaD
Crizotinib—JAK3—Immune System—CD4—Graves' disease	5.72e-05	0.000135	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL2RA—Graves' disease	5.7e-05	0.000135	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-DRB1—Graves' disease	5.67e-05	0.000134	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-E—Graves' disease	5.67e-05	0.000134	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TSHR—Graves' disease	5.66e-05	0.000134	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-A—Graves' disease	5.64e-05	0.000133	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-DRB1—Graves' disease	5.64e-05	0.000133	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL1B—Graves' disease	5.6e-05	0.000132	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-DRB1—Graves' disease	5.59e-05	0.000132	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD40—Graves' disease	5.54e-05	0.000131	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-DQB1—Graves' disease	5.49e-05	0.00013	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-A—Graves' disease	5.46e-05	0.000129	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTLA4—Graves' disease	5.46e-05	0.000129	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-DQB1—Graves' disease	5.46e-05	0.000129	CbGpPWpGaD
Crizotinib—PTK2—Immune System—ICAM1—Graves' disease	5.44e-05	0.000129	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—ICAM1—Graves' disease	5.41e-05	0.000128	CbGpPWpGaD
Crizotinib—YES1—Immune System—ICAM1—Graves' disease	5.37e-05	0.000127	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CXCL10—Graves' disease	5.31e-05	0.000125	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-DRB1—Graves' disease	5.31e-05	0.000125	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL1B—Graves' disease	5.28e-05	0.000125	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IFNG—Graves' disease	5.28e-05	0.000125	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CXCL10—Graves' disease	5.24e-05	0.000124	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—TNF—Graves' disease	5.21e-05	0.000123	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—IL2RA—Graves' disease	5.21e-05	0.000123	CbGpPWpGaD
Crizotinib—TYK2—Disease—HLA-A—Graves' disease	5.21e-05	0.000123	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IFNG—Graves' disease	5.2e-05	0.000123	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL2RA—Graves' disease	5.17e-05	0.000122	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-DRB1—Graves' disease	5.15e-05	0.000122	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—TNF—Graves' disease	5.14e-05	0.000121	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-DQB1—Graves' disease	5.13e-05	0.000121	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD8A—Graves' disease	5.12e-05	0.000121	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL2RA—Graves' disease	5.1e-05	0.00012	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CD4—Graves' disease	5.1e-05	0.00012	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD8A—Graves' disease	5.1e-05	0.00012	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—ICAM1—Graves' disease	5.09e-05	0.00012	CbGpPWpGaD
Crizotinib—BLK—Immune System—IFNG—Graves' disease	5.08e-05	0.00012	CbGpPWpGaD
Crizotinib—FGR—Immune System—IFNG—Graves' disease	5.06e-05	0.000119	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—CD4—Graves' disease	5.05e-05	0.000119	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—CD4—Graves' disease	5.03e-05	0.000119	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CD4—Graves' disease	5.03e-05	0.000119	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-E—Graves' disease	5.02e-05	0.000118	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-DRB1—Graves' disease	4.99e-05	0.000118	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CXCL10—Graves' disease	4.97e-05	0.000117	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—B3GNT2—Graves' disease	4.96e-05	0.000117	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TSHR—Graves' disease	4.95e-05	0.000117	CbGpPWpGaD
Crizotinib—TYK2—Immune System—ICAM1—Graves' disease	4.94e-05	0.000117	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GC—Graves' disease	4.94e-05	0.000117	CbGpPWpGaD
Crizotinib—CDK7—Disease—CD4—Graves' disease	4.94e-05	0.000116	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-B—Graves' disease	4.93e-05	0.000116	CbGpPWpGaD
Crizotinib—BLK—Immune System—CD4—Graves' disease	4.91e-05	0.000116	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD40—Graves' disease	4.91e-05	0.000116	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-B—Graves' disease	4.91e-05	0.000116	CbGpPWpGaD
Crizotinib—FGR—Immune System—CD4—Graves' disease	4.89e-05	0.000115	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL2RA—Graves' disease	4.88e-05	0.000115	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—CD4—Graves' disease	4.85e-05	0.000115	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTLA4—Graves' disease	4.83e-05	0.000114	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CXCL10—Graves' disease	4.82e-05	0.000114	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD8A—Graves' disease	4.79e-05	0.000113	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—ICAM1—Graves' disease	4.79e-05	0.000113	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—TNF—Graves' disease	4.73e-05	0.000112	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL2RA—Graves' disease	4.73e-05	0.000112	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL2RA—Graves' disease	4.73e-05	0.000112	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—CD4—Graves' disease	4.73e-05	0.000112	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL1B—Graves' disease	4.71e-05	0.000111	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL1B—Graves' disease	4.64e-05	0.00011	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2RA—Graves' disease	4.62e-05	0.000109	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-B—Graves' disease	4.61e-05	0.000109	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2RA—Graves' disease	4.6e-05	0.000109	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-A—Graves' disease	4.57e-05	0.000108	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-A—Graves' disease	4.54e-05	0.000107	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL1B—Graves' disease	4.53e-05	0.000107	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL1B—Graves' disease	4.52e-05	0.000107	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-DQB1—Graves' disease	4.5e-05	0.000106	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TSHR—Graves' disease	4.39e-05	0.000104	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2RA—Graves' disease	4.32e-05	0.000102	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-A—Graves' disease	4.27e-05	0.000101	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD8A—Graves' disease	4.2e-05	9.91e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-DRB1—Graves' disease	4.17e-05	9.85e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-DRB1—Graves' disease	4.15e-05	9.8e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IFNG—Graves' disease	4.14e-05	9.78e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CD4—Graves' disease	4.14e-05	9.77e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IFNG—Graves' disease	4.09e-05	9.64e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2RA—Graves' disease	4.06e-05	9.58e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-B—Graves' disease	4.04e-05	9.54e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2RA—Graves' disease	4e-05	9.45e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—ICAM1—Graves' disease	4e-05	9.45e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD4—Graves' disease	4e-05	9.45e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—ICAM1—Graves' disease	3.99e-05	9.41e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-DQB1—Graves' disease	3.98e-05	9.4e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD4—Graves' disease	3.98e-05	9.39e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD4—Graves' disease	3.95e-05	9.31e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—HLA-A—Graves' disease	3.95e-05	9.31e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL10—Graves' disease	3.91e-05	9.22e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-DRB1—Graves' disease	3.9e-05	9.22e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IFNG—Graves' disease	3.88e-05	9.15e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TNF—Graves' disease	3.83e-05	9.05e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TNF—Graves' disease	3.82e-05	9.01e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2RA—Graves' disease	3.8e-05	8.96e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2RA—Graves' disease	3.79e-05	8.93e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IFNG—Graves' disease	3.76e-05	8.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—ICAM1—Graves' disease	3.75e-05	8.84e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—B3GNT2—Graves' disease	3.75e-05	8.84e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-A—Graves' disease	3.74e-05	8.83e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD4—Graves' disease	3.74e-05	8.83e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD8A—Graves' disease	3.72e-05	8.78e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL1B—Graves' disease	3.7e-05	8.72e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2RA—Graves' disease	3.69e-05	8.7e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CD4—Graves' disease	3.67e-05	8.65e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL10—Graves' disease	3.66e-05	8.63e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL1B—Graves' disease	3.64e-05	8.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD4—Graves' disease	3.63e-05	8.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TNF—Graves' disease	3.59e-05	8.47e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-B—Graves' disease	3.58e-05	8.44e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD4—Graves' disease	3.52e-05	8.31e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	3.52e-05	8.31e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL1B—Graves' disease	3.46e-05	8.16e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HLA-A—Graves' disease	3.46e-05	8.16e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-DRB1—Graves' disease	3.42e-05	8.07e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL1B—Graves' disease	3.36e-05	7.92e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CD4—Graves' disease	3.35e-05	7.92e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2RA—Graves' disease	3.35e-05	7.91e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-A—Graves' disease	3.31e-05	7.82e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ICAM1—Graves' disease	3.28e-05	7.75e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL10—Graves' disease	3.2e-05	7.56e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HLA-A—Graves' disease	3.06e-05	7.22e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IFNG—Graves' disease	3.05e-05	7.19e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GC—Graves' disease	3.05e-05	7.19e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IFNG—Graves' disease	3.03e-05	7.16e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-DRB1—Graves' disease	3.03e-05	7.15e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2RA—Graves' disease	2.99e-05	7.05e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD4—Graves' disease	2.94e-05	6.95e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD4—Graves' disease	2.93e-05	6.91e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ICAM1—Graves' disease	2.91e-05	6.86e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IFNG—Graves' disease	2.85e-05	6.73e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL10—Graves' disease	2.83e-05	6.69e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2RA—Graves' disease	2.79e-05	6.6e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—Graves' disease	2.78e-05	6.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD4—Graves' disease	2.75e-05	6.5e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—Graves' disease	2.72e-05	6.41e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—Graves' disease	2.7e-05	6.38e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—Graves' disease	2.54e-05	6e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—Graves' disease	2.54e-05	6e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFNG—Graves' disease	2.5e-05	5.89e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2RA—Graves' disease	2.45e-05	5.78e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—Graves' disease	2.41e-05	5.69e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—B3GNT2—Graves' disease	2.31e-05	5.45e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—Graves' disease	2.23e-05	5.26e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—Graves' disease	2.23e-05	5.26e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNG—Graves' disease	2.21e-05	5.22e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2RA—Graves' disease	2.17e-05	5.11e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—Graves' disease	2.14e-05	5.04e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—Graves' disease	1.97e-05	4.65e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—Graves' disease	1.97e-05	4.65e-05	CbGpPWpGaD
